Clinical development on the frontier: gene therapy for duchenne muscular dystrophy
Open Access
- 12 February 2020
- journal article
- review article
- Published by Taylor & Francis in Expert Opinion on Biological Therapy
- Vol. 20 (3) , 263-274
Abstract
Introduction: The development of adeno-associated virus (AAV) vectors as safe vehicles for in vivo delivery of therapeutic genes has been a major milestone in the advancement of gene therapy, enabling a promising strategy for ameliorating a wide range of diseases, including Duchenne muscular dystrophy (DMD). Areas covered: Based on experience with development of a gene transfer therapy agent for DMD, we discuss ways in which gene therapy for rare disease challenges traditional clinical development paradigms, and recommend a step-wise approach for design and evaluation to support broader applicability of gene therapy. Expert opinion: The gene therapy development approach should intentionally design the therapeutic construct and the clinical study to systematically evaluate agent delivery, safety, and efficacy. Rigorous preclinical work is essential for establishing an effective gene delivery platform and determining the efficacious dose. Clinical studies should thoroughly evaluate transduction, on-target transgene expression at the tissue and cellular level, and functional efficacy.Keywords
This publication has 70 references indexed in Scilit:
- Gene therapy for Duchenne muscular dystrophyCurrent Opinion in Neurology, 2012
- Exon skipping and dystrophin restoration in patients with Duchenne muscular dystrophy after systemic phosphorodiamidate morpholino oligomer treatment: an open-label, phase 2, dose-escalation studyThe Lancet, 2011
- The Natural History of Cardiac and Pulmonary Function Decline in Patients With Duchenne Muscular DystrophySpine, 2011
- Assessing the potential for AAV vector genotoxicity in a murine modelBlood, 2011
- Dystrophin Immunity in Duchenne's Muscular DystrophyNew England Journal of Medicine, 2010
- Insertional mutagenesis combined with acquired somatic mutations causes leukemogenesis following gene therapy of SCID-X1 patientsJournal of Clinical Investigation, 2008
- A translational approach for limb vascular delivery of the micro-dystrophin gene without high volume or high pressure for treatment of Duchenne muscular dystrophyJournal of Translational Medicine, 2007
- Occurrence of leukaemia following gene therapy of X-linked SCIDNature Reviews Cancer, 2003
- Progress and problems with the use of viral vectors for gene therapyNature Reviews Genetics, 2003
- A Serious Adverse Event after Successful Gene Therapy for X-Linked Severe Combined ImmunodeficiencyNew England Journal of Medicine, 2003